INT262114

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2009
Last Reported 2009
Negated 0
Speculated 1
Reported most in Body
Documents 1
Total Number 11
Disease Relevance 4.72
Pain Relevance 1.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Nr1i2) DNA binding (Nr1i2)
Anatomy Link Frequency
bile 1
Nr1i2 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 99 97.68 Very High Very High Very High
Bile 429 97.60 Very High Very High Very High
dexamethasone 22 96.68 Very High Very High Very High
antagonist 77 94.16 High High
Inflammation 187 92.52 High High
anticonvulsant 11 75.60 Quite High
Inflammatory stimuli 11 68.16 Quite High
antidepressant 33 37.20 Quite Low
Taxol 22 33.84 Quite Low
Analgesic 11 9.80 Low Low
Disease Link Frequency Relevance Heat
Targeted Disruption 187 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 33 99.80 Very High Very High Very High
Hyperlipidemia 33 99.12 Very High Very High Very High
Endometriosis (extended) 33 98.20 Very High Very High Very High
Cancer 198 96.92 Very High Very High Very High
Cardiovascular Disease 11 96.72 Very High Very High Very High
Toxicity 44 96.08 Very High Very High Very High
INFLAMMATION 132 92.52 High High
Apoptosis 55 88.64 High High
Hepatotoxicity 22 87.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, SXR downregulation would reduce expression of CYP3A4, thereby increasing local estrogen levels and/or increasing sensitivity of estrogen receptor to estradiol [Cheng et al., 2001].
Negative_regulation (downregulation) of SXR
1) Confidence 0.55 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.48 Pain Relevance 0
A 6-bp deletion in the promoter region of NR1I2 at a putative hepatic nuclear factor binding site was suggested to have a possible influence on the promoter region and potentially inhibit SXR promoter activity and downregulate expression of SXR target genes [Lamba et al., 2008; Uno et al., 2003].
Negative_regulation (inhibit) of SXR
2) Confidence 0.55 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.16 Pain Relevance 0.04
Moreover, they found that downregulation of SXR significantly enhanced the proliferation of endometrial cancer cells in the presence of estradiol.
Negative_regulation (downregulation) of SXR associated with endometriosis (extended)
3) Confidence 0.55 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.49 Pain Relevance 0
Inhibition of SXR activity by chemicals such as highly chlorinated PCBs will reduce metabolism of endo- and xenobiotic compounds, as well as the metabolism of the antagonists themselves.
Negative_regulation (Inhibition) of SXR associated with antagonist
4) Confidence 0.55 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0 Pain Relevance 0.10
Therefore, it was suggested that SXR downregulation might be a way to sensitize these cells to paclitaxel and overcome their resistance to it through the inhibition of drug metabolism and/or transport/efflux of this drug [Masuyama et al., 2007].
Negative_regulation (downregulation) of SXR
5) Confidence 0.55 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.65 Pain Relevance 0
Mice lacking both FXR and SXR exhibit more severe disturbances in cholesterol, lipid and bile acid metabolism than mice lacking only one of the two nuclear receptors [Guo et al., 2003].
Negative_regulation (lacking) of SXR in bile associated with bile
6) Confidence 0.41 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.58 Pain Relevance 0.33
Therefore, it would be of great interest to investigate whether SFN is the active ingredient in broccoli that lowers cholesterol levels and whether it does so by inhibiting SXR activity.
Spec (whether) Negative_regulation (inhibiting) of SXR
7) Confidence 0.41 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.33 Pain Relevance 0.08
Targeted disruption of SXR abolishes the induction of CYP3A genes in response to prototypic inducers such as dexamethasone or PCN.
Negative_regulation (disruption) of SXR associated with targeted disruption and dexamethasone
8) Confidence 0.41 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.40 Pain Relevance 0.19
SXR inhibited NF-?
Negative_regulation (inhibited) of SXR
9) Confidence 0.41 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.59 Pain Relevance 0.26
SOD and CAT may not be direct transcriptional targets of SXR and the mechanism of SXR-mediated downregulation of SOD and CAT activities remains to be determined.
Negative_regulation (mechanism) of SXR
10) Confidence 0.40 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.23 Pain Relevance 0.05
In addition, treatment of HIV patients with ritonavir, one of the first commercially available HIV protease inhibitors and a potent SXR activator, can cause hyperlipidemia and may be associated with increased risk of cardiovascular disease [Barbaro, 2006; Carr et al., 1998a; Carr et al., 1998b; Shafran et al., 2005].
Negative_regulation (inhibitors) of SXR associated with cardiovascular disease, acquired immune deficiency syndrome or hiv infection and hyperlipidemia
11) Confidence 0.35 Published 2009 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2646121 Disease Relevance 0.81 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox